Literature DB >> 7795555

Concise overview of the clinical pharmacokinetics of dideoxynucleoside antiretroviral agents.

D M Burger1, P L Meenhorst, J H Beijnen.   

Abstract

In this paper aspects of the clinical pharmacokinetics of the antiretroviral agents zidovudine, didanosine and zalcitabine are reviewed. Special attention is paid to possibly altered pharmacokinetics in special circumstances, such as hepatic and renal dysfunction, pregnancy, stage of disease, etc. The dideoxynucleoside antiretroviral agents have some clinical pharmacokinetic properties in common (rapid absorption and elimination), but substantial differences exist in their degree of absorption, metabolism and penetration into the cerebrospinal fluid. All agents display wide interpatient variability in pharmacokinetic parameters. The relevance of therapeutic drug monitoring of antiretroviral agents is also discussed.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7795555     DOI: 10.1007/bf01875051

Source DB:  PubMed          Journal:  Pharm World Sci        ISSN: 0928-1231


  48 in total

1.  Pharmacokinetics of zidovudine phosphorylation in patients infected with the human immunodeficiency virus.

Authors:  B N Stretcher; A J Pesce; P E Hurtubise; P T Frame
Journal:  Ther Drug Monit       Date:  1992-08       Impact factor: 3.681

2.  Decreased and variable systemic availability of zidovudine in patients with AIDS if administered with a meal.

Authors:  E Lotterer; M Ruhnke; M Trautmann; R Beyer; F E Bauer
Journal:  Eur J Clin Pharmacol       Date:  1991       Impact factor: 2.953

3.  Clinical pharmacology of 2',3'-dideoxyinosine in human immunodeficiency virus-infected children.

Authors:  F M Balis; P A Pizzo; K M Butler; M E Hawkins; P Brouwers; R N Husson; F Jacobsen; S M Blaney; J Gress; P Jarosinski
Journal:  J Infect Dis       Date:  1992-01       Impact factor: 5.226

4.  Effects of standard breakfast on pharmacokinetics of oral zidovudine in patients with AIDS.

Authors:  M Ruhnke; F E Bauer; M Seifert; M Trautmann; H Hille; P Koeppe
Journal:  Antimicrob Agents Chemother       Date:  1993-10       Impact factor: 5.191

5.  Pharmacokinetics of zidovudine in patients with liver cirrhosis.

Authors:  A M Taburet; S Naveau; G Zorza; J N Colin; J F Delfraissy; J C Chaput; E Singlas
Journal:  Clin Pharmacol Ther       Date:  1990-06       Impact factor: 6.875

Review 6.  Didanosine.

Authors:  M J Shelton; A M O'Donnell; G D Morse
Journal:  Ann Pharmacother       Date:  1992-05       Impact factor: 3.154

7.  Transfer and metabolism of dideoxyinosine by the perfused human placenta.

Authors:  J Dancis; J D Lee; S Mendoza; L Liebes
Journal:  J Acquir Immune Defic Syndr (1988)       Date:  1993-01

8.  Didanosine pharmacokinetics in patients with normal and impaired renal function: influence of hemodialysis.

Authors:  E Singlas; A M Taburet; F Borsa Lebas; O Parent de Curzon; A Sobel; P Chauveau; B Viron; R al Khayat; J L Poignet; F Mignon
Journal:  Antimicrob Agents Chemother       Date:  1992-07       Impact factor: 5.191

9.  Metabolism of didanosine (ddI) by erythrocytes: pharmacokinetic implications.

Authors:  M Barry; D Back; S Ormesher; N Beeching; F Nye
Journal:  Br J Clin Pharmacol       Date:  1993-07       Impact factor: 4.335

10.  Pharmacokinetics of zidovudine in end-stage renal disease: influence of haemodialysis.

Authors:  J Pachon; J M Cisneros; J R Castillo; F Garcia-Pesquera; E Cañas; P Viciana
Journal:  AIDS       Date:  1992-08       Impact factor: 4.177

View more
  3 in total

Review 1.  Neuropsychiatric Effects of HIV Antiviral Medications.

Authors:  Glenn J Treisman; Olivia Soudry
Journal:  Drug Saf       Date:  2016-10       Impact factor: 5.606

Review 2.  Pharmacokinetic individualisation of zidovudine therapy. Current state of pharmacokinetic-pharmacodynamic relationships.

Authors:  R M Hoetelmans; D M Burger; P L Meenhorst; J H Beijnen
Journal:  Clin Pharmacokinet       Date:  1996-04       Impact factor: 6.447

Review 3.  Clinical implications of CNS penetration of antiretroviral drugs.

Authors:  Heather E Wynn; Richard C Brundage; Courtney V Fletcher
Journal:  CNS Drugs       Date:  2002       Impact factor: 5.749

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.